Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.
Identifieur interne : 001530 ( Main/Corpus ); précédent : 001529; suivant : 001531Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.
Auteurs : Efstathios Kastritis ; Ashutosh Wechalekar ; Stefan Schönland ; Vaishali Sanchorawala ; Giampaolo Merlini ; Giovanni Palladini ; Monique Minnema ; Murielle Roussel ; Arnaud Jaccard ; Ute Hegenbart ; Shaji Kumar ; Maria T. Cibeira ; Joan Blade ; Meletios A. DimopoulosSource :
- British journal of haematology [ 1365-2141 ] ; 2020.
English descriptors
- KwdEn :
- Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Health Services Accessibility (MeSH), Humans (MeSH), Immunoglobulin Light-chain Amyloidosis (complications), Immunoglobulin Light-chain Amyloidosis (drug therapy), Immunologic Factors (adverse effects), Immunologic Factors (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), SARS-CoV-2 (MeSH).
- MESH :
- chemical , adverse effects : Antiviral Agents, Immunologic Factors.
- chemical , therapeutic use : Antiviral Agents, Immunologic Factors.
- complications : Coronavirus Infections, Immunoglobulin Light-chain Amyloidosis, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Immunoglobulin Light-chain Amyloidosis, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Health Services Accessibility, Humans, Pandemics, SARS-CoV-2.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated coronavirus disease 2019 (COVID-19) is primarily manifested as a respiratory tract infection, but may affect and cause complications in multiple organ systems (cardiovascular, gastrointestinal, kidneys, haematopoietic and immune systems), while no proven specific therapy exists. The challenges associated with COVID-19 are even greater for patients with light chain (AL) amyloidosis, a rare multisystemic disease affecting the heart, kidneys, liver, gastrointestinal and nervous system. Patients with AL amyloidosis may need to receive chemotherapy, which probably increases infection risk. Management of COVID-19 may be particularly challenging in patients with AL amyloidosis, who often present with cardiac dysfunction, nephrotic syndrome, neuropathy, low blood pressure and gastrointestinal symptoms. In addition, patients with AL amyloidosis may be more susceptible to toxicities of drugs used to manage COVID-19. Access to health care may be difficult or limited, diagnosis of AL amyloidosis may be delayed with detrimental consequences and treatment administration may need modification. Both patients and treating physicians need to adapt in a new reality.
DOI: 10.1111/bjh.16898
PubMed: 32480420
PubMed Central: PMC7300844
Links to Exploration step
pubmed:32480420Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.</title><author><name sortKey="Kastritis, Efstathios" sort="Kastritis, Efstathios" uniqKey="Kastritis E" first="Efstathios" last="Kastritis">Efstathios Kastritis</name><affiliation><nlm:affiliation>Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Wechalekar, Ashutosh" sort="Wechalekar, Ashutosh" uniqKey="Wechalekar A" first="Ashutosh" last="Wechalekar">Ashutosh Wechalekar</name><affiliation><nlm:affiliation>National Amyloidosis Centre, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Schonland, Stefan" sort="Schonland, Stefan" uniqKey="Schonland S" first="Stefan" last="Schönland">Stefan Schönland</name><affiliation><nlm:affiliation>Medical Department V, Amyloidosis Centre, University Hospital Heidelberg, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Sanchorawala, Vaishali" sort="Sanchorawala, Vaishali" uniqKey="Sanchorawala V" first="Vaishali" last="Sanchorawala">Vaishali Sanchorawala</name><affiliation><nlm:affiliation>Amyloidosis Center, School of Medicine and Boston Medical Center, Boston University, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Merlini, Giampaolo" sort="Merlini, Giampaolo" uniqKey="Merlini G" first="Giampaolo" last="Merlini">Giampaolo Merlini</name><affiliation><nlm:affiliation>Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo", University of Pavia, Pavia, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Palladini, Giovanni" sort="Palladini, Giovanni" uniqKey="Palladini G" first="Giovanni" last="Palladini">Giovanni Palladini</name><affiliation><nlm:affiliation>Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo", University of Pavia, Pavia, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Minnema, Monique" sort="Minnema, Monique" uniqKey="Minnema M" first="Monique" last="Minnema">Monique Minnema</name><affiliation><nlm:affiliation>Department of Hematology, UMC Utrecht Cancer Center, Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Roussel, Murielle" sort="Roussel, Murielle" uniqKey="Roussel M" first="Murielle" last="Roussel">Murielle Roussel</name><affiliation><nlm:affiliation>Clinical Hematology, IUC Oncopole/CHU Toulouse, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Jaccard, Arnaud" sort="Jaccard, Arnaud" uniqKey="Jaccard A" first="Arnaud" last="Jaccard">Arnaud Jaccard</name><affiliation><nlm:affiliation>CHU Poitiers, Poitiers, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hegenbart, Ute" sort="Hegenbart, Ute" uniqKey="Hegenbart U" first="Ute" last="Hegenbart">Ute Hegenbart</name><affiliation><nlm:affiliation>Medical Department V, Amyloidosis Centre, University Hospital Heidelberg, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kumar, Shaji" sort="Kumar, Shaji" uniqKey="Kumar S" first="Shaji" last="Kumar">Shaji Kumar</name><affiliation><nlm:affiliation>Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cibeira, Maria T" sort="Cibeira, Maria T" uniqKey="Cibeira M" first="Maria T" last="Cibeira">Maria T. Cibeira</name><affiliation><nlm:affiliation>Hematology Department, Amyloidosis and Myeloma Unit, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Blade, Joan" sort="Blade, Joan" uniqKey="Blade J" first="Joan" last="Blade">Joan Blade</name><affiliation><nlm:affiliation>Hematology Department, Amyloidosis and Myeloma Unit, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A" last="Dimopoulos">Meletios A. Dimopoulos</name><affiliation><nlm:affiliation>Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32480420</idno><idno type="pmid">32480420</idno><idno type="doi">10.1111/bjh.16898</idno><idno type="pmc">PMC7300844</idno><idno type="wicri:Area/Main/Corpus">001530</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001530</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.</title><author><name sortKey="Kastritis, Efstathios" sort="Kastritis, Efstathios" uniqKey="Kastritis E" first="Efstathios" last="Kastritis">Efstathios Kastritis</name><affiliation><nlm:affiliation>Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Wechalekar, Ashutosh" sort="Wechalekar, Ashutosh" uniqKey="Wechalekar A" first="Ashutosh" last="Wechalekar">Ashutosh Wechalekar</name><affiliation><nlm:affiliation>National Amyloidosis Centre, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Schonland, Stefan" sort="Schonland, Stefan" uniqKey="Schonland S" first="Stefan" last="Schönland">Stefan Schönland</name><affiliation><nlm:affiliation>Medical Department V, Amyloidosis Centre, University Hospital Heidelberg, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Sanchorawala, Vaishali" sort="Sanchorawala, Vaishali" uniqKey="Sanchorawala V" first="Vaishali" last="Sanchorawala">Vaishali Sanchorawala</name><affiliation><nlm:affiliation>Amyloidosis Center, School of Medicine and Boston Medical Center, Boston University, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Merlini, Giampaolo" sort="Merlini, Giampaolo" uniqKey="Merlini G" first="Giampaolo" last="Merlini">Giampaolo Merlini</name><affiliation><nlm:affiliation>Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo", University of Pavia, Pavia, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Palladini, Giovanni" sort="Palladini, Giovanni" uniqKey="Palladini G" first="Giovanni" last="Palladini">Giovanni Palladini</name><affiliation><nlm:affiliation>Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo", University of Pavia, Pavia, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Minnema, Monique" sort="Minnema, Monique" uniqKey="Minnema M" first="Monique" last="Minnema">Monique Minnema</name><affiliation><nlm:affiliation>Department of Hematology, UMC Utrecht Cancer Center, Utrecht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Roussel, Murielle" sort="Roussel, Murielle" uniqKey="Roussel M" first="Murielle" last="Roussel">Murielle Roussel</name><affiliation><nlm:affiliation>Clinical Hematology, IUC Oncopole/CHU Toulouse, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Jaccard, Arnaud" sort="Jaccard, Arnaud" uniqKey="Jaccard A" first="Arnaud" last="Jaccard">Arnaud Jaccard</name><affiliation><nlm:affiliation>CHU Poitiers, Poitiers, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hegenbart, Ute" sort="Hegenbart, Ute" uniqKey="Hegenbart U" first="Ute" last="Hegenbart">Ute Hegenbart</name><affiliation><nlm:affiliation>Medical Department V, Amyloidosis Centre, University Hospital Heidelberg, Heidelberg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kumar, Shaji" sort="Kumar, Shaji" uniqKey="Kumar S" first="Shaji" last="Kumar">Shaji Kumar</name><affiliation><nlm:affiliation>Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cibeira, Maria T" sort="Cibeira, Maria T" uniqKey="Cibeira M" first="Maria T" last="Cibeira">Maria T. Cibeira</name><affiliation><nlm:affiliation>Hematology Department, Amyloidosis and Myeloma Unit, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Blade, Joan" sort="Blade, Joan" uniqKey="Blade J" first="Joan" last="Blade">Joan Blade</name><affiliation><nlm:affiliation>Hematology Department, Amyloidosis and Myeloma Unit, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A" last="Dimopoulos">Meletios A. Dimopoulos</name><affiliation><nlm:affiliation>Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.</nlm:affiliation></affiliation></author></analytic><series><title level="j">British journal of haematology</title><idno type="eISSN">1365-2141</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (epidemiology)</term><term>Health Services Accessibility (MeSH)</term><term>Humans (MeSH)</term><term>Immunoglobulin Light-chain Amyloidosis (complications)</term><term>Immunoglobulin Light-chain Amyloidosis (drug therapy)</term><term>Immunologic Factors (adverse effects)</term><term>Immunologic Factors (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (epidemiology)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Immunoglobulin Light-chain Amyloidosis</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Immunoglobulin Light-chain Amyloidosis</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Health Services Accessibility</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated coronavirus disease 2019 (COVID-19) is primarily manifested as a respiratory tract infection, but may affect and cause complications in multiple organ systems (cardiovascular, gastrointestinal, kidneys, haematopoietic and immune systems), while no proven specific therapy exists. The challenges associated with COVID-19 are even greater for patients with light chain (AL) amyloidosis, a rare multisystemic disease affecting the heart, kidneys, liver, gastrointestinal and nervous system. Patients with AL amyloidosis may need to receive chemotherapy, which probably increases infection risk. Management of COVID-19 may be particularly challenging in patients with AL amyloidosis, who often present with cardiac dysfunction, nephrotic syndrome, neuropathy, low blood pressure and gastrointestinal symptoms. In addition, patients with AL amyloidosis may be more susceptible to toxicities of drugs used to manage COVID-19. Access to health care may be difficult or limited, diagnosis of AL amyloidosis may be delayed with detrimental consequences and treatment administration may need modification. Both patients and treating physicians need to adapt in a new reality.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32480420</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2141</ISSN><JournalIssue CitedMedium="Internet"><Volume>190</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>08</Month></PubDate></JournalIssue><Title>British journal of haematology</Title><ISOAbbreviation>Br J Haematol</ISOAbbreviation></Journal><ArticleTitle>Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.</ArticleTitle><Pagination><MedlinePgn>346-357</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bjh.16898</ELocationID><Abstract><AbstractText>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated coronavirus disease 2019 (COVID-19) is primarily manifested as a respiratory tract infection, but may affect and cause complications in multiple organ systems (cardiovascular, gastrointestinal, kidneys, haematopoietic and immune systems), while no proven specific therapy exists. The challenges associated with COVID-19 are even greater for patients with light chain (AL) amyloidosis, a rare multisystemic disease affecting the heart, kidneys, liver, gastrointestinal and nervous system. Patients with AL amyloidosis may need to receive chemotherapy, which probably increases infection risk. Management of COVID-19 may be particularly challenging in patients with AL amyloidosis, who often present with cardiac dysfunction, nephrotic syndrome, neuropathy, low blood pressure and gastrointestinal symptoms. In addition, patients with AL amyloidosis may be more susceptible to toxicities of drugs used to manage COVID-19. Access to health care may be difficult or limited, diagnosis of AL amyloidosis may be delayed with detrimental consequences and treatment administration may need modification. Both patients and treating physicians need to adapt in a new reality.</AbstractText><CopyrightInformation>© 2020 British Society for Haematology and John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kastritis</LastName><ForeName>Efstathios</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8191-5832</Identifier><AffiliationInfo><Affiliation>Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wechalekar</LastName><ForeName>Ashutosh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Amyloidosis Centre, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schönland</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Department V, Amyloidosis Centre, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchorawala</LastName><ForeName>Vaishali</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-6307-2445</Identifier><AffiliationInfo><Affiliation>Amyloidosis Center, School of Medicine and Boston Medical Center, Boston University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merlini</LastName><ForeName>Giampaolo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo", University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palladini</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo", University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minnema</LastName><ForeName>Monique</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, UMC Utrecht Cancer Center, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roussel</LastName><ForeName>Murielle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Hematology, IUC Oncopole/CHU Toulouse, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaccard</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CHU Poitiers, Poitiers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hegenbart</LastName><ForeName>Ute</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Medical Department V, Amyloidosis Centre, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Shaji</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5392-9284</Identifier><AffiliationInfo><Affiliation>Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cibeira</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Hematology Department, Amyloidosis and Myeloma Unit, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blade</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hematology Department, Amyloidosis and Myeloma Unit, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimopoulos</LastName><ForeName>Meletios A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-8990-3254</Identifier><AffiliationInfo><Affiliation>Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Haematol</MedlineTA><NlmUniqueID>0372544</NlmUniqueID><ISSNLinking>0007-1048</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075363" MajorTopicYN="N">Immunoglobulin Light-chain Amyloidosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">amyloidosis</Keyword><Keyword MajorTopicYN="Y">hydroxychloroquine</Keyword><Keyword MajorTopicYN="Y">remdesivir</Keyword><Keyword MajorTopicYN="Y">tocilizumab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32480420</ArticleId><ArticleId IdType="doi">10.1111/bjh.16898</ArticleId><ArticleId IdType="pmc">PMC7300844</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system. A Review. JAMA Cardiol. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-7.</Citation></Reference><Reference><Citation>Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335-7.</Citation></Reference><Reference><Citation>Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020;e200980.</Citation></Reference><Reference><Citation>Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of severity in cancer patients with COVID-19 illness. medRxiv. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Merlini G, Dispenzieri A, Sanchorawala V, Schonland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4:38.</Citation></Reference><Reference><Citation>Kristinsson SY, Tang M, Pfeiffer RM, Bjorkholm M, Goldin LR, Blimark C, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97:854-8.</Citation></Reference><Reference><Citation>Pietrantonio F, Garassino MC. Caring for patients with cancer during the COVID-19 outbreak in Italy. JAMA Oncol. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>2020 [cited 2020 Apr 28]. Available from: https://cms.cws.net/content/isaamyloidosis.org/files/ISA%20recommendations%20Covid-19%20v_%203_3.pdf</Citation></Reference><Reference><Citation>Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-74.</Citation></Reference><Reference><Citation>Pan XW, Xu D, Zhang H, Zhou W, Wang LH, Cui XG. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-4.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.</Citation></Reference><Reference><Citation>Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9:687-90.</Citation></Reference><Reference><Citation>Ciceri F, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020 Apr 15 Online ahead of print. PMID: 32294809.</Citation></Reference><Reference><Citation>Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 2015;32:920-8.</Citation></Reference><Reference><Citation>Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020;382:2049-55.</Citation></Reference><Reference><Citation>Moghadas SM, Shoukat A, Fitzpatrick MC, Wells CR, Sah P, Pandey A, et al. Projecting hospital utilization during the COVID-19 outbreaks in the United States. Proc Natl Acad Sci. 2020;117:9122-6.</Citation></Reference><Reference><Citation>Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;e201017.</Citation></Reference><Reference><Citation>Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;e200950.</Citation></Reference><Reference><Citation>Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.</Citation></Reference><Reference><Citation>Stamatelopoulos K, Georgiopoulos G, Athanasouli F, Nikolaou PE, Lykka M, Roussou M, et al. Reactive vasodilation predicts mortality in primary systemic light-chain amyloidosis. Circ Res. 2019;125:744-58.</Citation></Reference><Reference><Citation>Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121:3420-7.</Citation></Reference><Reference><Citation>Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94:1008-10.</Citation></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.</Citation></Reference><Reference><Citation>Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020;ehaa190.</Citation></Reference><Reference><Citation>Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135:1357-77.</Citation></Reference><Reference><Citation>Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is there an association between COVID-19 mortality and the renin-angiotensin system - a call for epidemiologic investigations. Clin Infect Dis. 2020;ciaa329.</Citation></Reference><Reference><Citation>Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382:1653-9.</Citation></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID- 19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Perinel S, Launay M, Botelho-Nevers E, Diconne E, Louf-Durier A, Lachand R, et al. Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients. Clin Infect Dis. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Yazdany J, Kim AH. Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann Intern Med. 2020;172:754-5.</Citation></Reference><Reference><Citation>Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020;192:E450-3.</Citation></Reference><Reference><Citation>Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Giudicessi JR, Noseworthy PA, Friedman PA Ackerman MJ. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clin Proc. 2020;95:1213-21.</Citation></Reference><Reference><Citation>Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID- 19: a single center experience. J Med Virol. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4:1307-10.</Citation></Reference><Reference><Citation>Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15:813-22.</Citation></Reference><Reference><Citation>Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 2020;72:31-40.</Citation></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569-78.</Citation></Reference><Reference><Citation>Bever KM, Masha LI, Sun F, Stern L, Havasi A, Berk JL, et al. Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis. Haematologica. 2016;101:86-90.</Citation></Reference><Reference><Citation>Kastritis E, Gavriatopoulou M, Roussou M, Migkou M, Fotiou D, Ziogas DC, et al. Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy. Am J Hematol. 2017;92:632-9.</Citation></Reference><Reference><Citation>Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124:2325-32.</Citation></Reference><Reference><Citation>Sidana S, Tandon N, Gertz MA, Dispenzieri A, Ramirez-Alvarado M, Murray DL, et al. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. Br J Haematol. 2019;185:701-7.</Citation></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20.</Citation></Reference><Reference><Citation>Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:829-38.</Citation></Reference><Reference><Citation>Thorogood N, Atwal S, Mills W, Jenner M, Lewis DA, Cavenagh JD, et al. The risk of antimalarials in patients with renal failure. Postgrad Med J. 2007;83:e8.</Citation></Reference><Reference><Citation>Tett S, McLachlan A, Day R, Cutler D. Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine. Agents Actions Suppl. 1993;44:145-90.</Citation></Reference><Reference><Citation>Jallouli, M, Galicier, L, Zahr, N, Aumaitre, O, Frances, C, Le Guern, V, et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 2015;67:2176-84.</Citation></Reference><Reference><Citation>McLachlan AJ, Cutler DJ, Tett SE. Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites. Eur J Clin Pharmacol. 1993;44:481-4.</Citation></Reference><Reference><Citation>Leung N, Kumar SK, Glavey SV, Dispenzieri A, Lacy MQ, Buadi FK, et al. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrol Dial Transplant. 2016;31:1284-9.</Citation></Reference><Reference><Citation>Angel-Korman A, Stern L, Sarosiek S, Sloan JM, Doros G, Sanchorawala V, et al. Long-term outcome of kidney transplantation in AL amyloidosis. Kidney Int. 2019;95:405-11.</Citation></Reference><Reference><Citation>Kliger AS, Silberzweig J. Mitigating risk of COVID-19 in dialysis facilities. Clin J Am Soc Nephrol. 2020;15:707-9.</Citation></Reference><Reference><Citation>Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost. 2020;18:786-7.</Citation></Reference><Reference><Citation>Choufani EB, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright DG, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001;97:1885-7.</Citation></Reference><Reference><Citation>Kos CA, Ward JE, Malek K, Sanchorawala V, Wright DG, O'Hara C, et al. Association of acquired von Willebrand syndrome with AL amyloidosis. Am J Hematol. 2007;82:363-7.</Citation></Reference><Reference><Citation>Pudusseri A, Sanchorawala V, Sloan JM, Bever KM, Doros G, Kataria S, et al. Prevalence and prognostic value of D-dimer elevation in patients with AL amyloidosis. Am J Hematol. 2019;94:1098-103.</Citation></Reference><Reference><Citation>Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B, et al. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol. 2011;301:H2305-H2312.</Citation></Reference><Reference><Citation>Sattianayagam PT, Lane T, Fox Z, Petrie A, Gibbs SD, Pinney JH, et al. A prospective study of nutritional status in immunoglobulin light chain amyloidosis. Haematologica. 2013;98:136-40.</Citation></Reference><Reference><Citation>D'Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management. Clin Gastroenterol Hepatol. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Chen C, Gao G, Xu Y, Pu L, Wang Q, Wang L, et al. SARS-CoV-2-positive sputum and feces after conversion of pharyngeal samples in patients with COVID-19. Ann Intern Med. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Chen Y, Chen L, Deng Q, Zhang G, Wu K, Ni L, et al. The presence of SARS-CoV-2 RNA in feces of COVID-19 patients. J Med Virol. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13.</Citation></Reference><Reference><Citation>Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5:428-30.</Citation></Reference><Reference><Citation>Kokotis P, Manios E, Schmelz M, Fotiou D, Dialoupi I, Gavriatopoulou M, et al. Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. Amyloid. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382:2268-70.</Citation></Reference><Reference><Citation>Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641-54.</Citation></Reference><Reference><Citation>Ritchie AI, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Lancet. 2020;395:1111.</Citation></Reference><Reference><Citation>D'Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl; 2020;26:832-4.</Citation></Reference><Reference><Citation>Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. Management of patients on dialysis and with kidney transplant during SARS-COV-2 (COVID-19) pandemic in Brescia, Italy. Kidney Int Rep. 2020;5:580-5.</Citation></Reference><Reference><Citation>Sharpley FA, De-Silva D, Mahmood S, Sachchithanantham S, Ramsay I, Garcia Mingo A, et al. Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis. Eur J Haematol. 2020;104:230-5.</Citation></Reference><Reference><Citation>Balsman E. Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: a case report. J Oncol Pharm Pract. 2017;23:545-8.</Citation></Reference><Reference><Citation>Zappasodi P, Dore R, Castagnola C, Astori C, Varettoni M, Mangiacavalli S, et al. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J Clin Oncol. 2007;25:3380-1.</Citation></Reference><Reference><Citation>Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414-23.</Citation></Reference><Reference><Citation>Zagouri F, Roussou M, Kastritis E, Koureas A, Tsokou E, Migkou M, et al. Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. Am J Hematol. 2011;86:882-4.</Citation></Reference><Reference><Citation>Kimmich CR, Terzer T, Benner A, Dittrich T, Veelken K, Carpinteiro A, et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic range albuminuria. Blood. 2020;135:1517-30.</Citation></Reference><Reference><Citation>Roussel M, Merlini G, Chevret S, Arnulf B, Stoppa AM, Perrot A, et al. A prospective phase 2 of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 2020;135:1531-40.</Citation></Reference><Reference><Citation>Sanchorawala V, Sarosiek S, Schulman A, Mistark M, Migre ME, Cruz R, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a Phase 2 study. Blood. 2020;135:1541-7.</Citation></Reference><Reference><Citation>Palladini G, Merlini G. When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression. Blood Adv. 2019;3:212-5.</Citation></Reference><Reference><Citation>Sanchorawala V. Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details. Blood Adv. 2019;3:216-8.</Citation></Reference><Reference><Citation>Banna G, Curioni-Fontecedro A, Friedlaender A, Addeo A. How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere. ESMO Open. 2020;5:e000765.</Citation></Reference><Reference><Citation>Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol. 2020;17:268-70.</Citation></Reference><Reference><Citation>Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, et al. A Randomized Phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis. Blood. 2016;128:646.</Citation></Reference><Reference><Citation>Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119:4391-4.</Citation></Reference><Reference><Citation>Struck RF, Alberts DS, Horne K, Phillips JG, Peng YM, Roe DJ. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res. 1987;47:2723-6.</Citation></Reference><Reference><Citation>Barr H, Dempsey J, Waller A, Huang Y, Williams N, Sharma N, et al. Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia. 2018;32:2495-518.</Citation></Reference><Reference><Citation>Palladini G, Kastritis E, Maurer MS, Zonder JA, Minnema MC, Wechalekar AD, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020 [Epub ahead of print].</Citation></Reference><Reference><Citation>Dispenzieri A, Kastritis E, Wechalekar A, Schönland SO, Kim K, Sanchorawala V, et al. Primary results from the phase 3 tourmaline-AL1 trial of ixazomib-dexamethasone versus physician's choice of therapy in patients (Pts) with relapsed/refractory primary systemic AL amyloidosis (RRAL). Blood. 2019;134:139.</Citation></Reference><Reference><Citation>Larocca A, Salvini M, De Paoli L, Cascavilla N, Benevolo G, Galli M, et al. Efficacy and feasibility of dose/schedule-adjusted Rd-R Vs. continuous Rd in elderly and intermediate-fit newly diagnosed multiple myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III randomized study. Blood. 2018;132(Suppl):305.</Citation></Reference><Reference><Citation>Manwani R, Hegenbart U, Mahmood S, Sachchithanantham S, Kyriakou C, Yong K, et al. Deferred autologous stem cell transplantation in systemic AL amyloidosis. Blood Cancer J. 2018;8:101.</Citation></Reference><Reference><Citation>Trachtenberg BH, Kamble RT, Rice L, Araujo-Gutierrez R, Bhimaraj A, Guha A, et al. Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis. Am J Transplant. 2019;19:2900-9.</Citation></Reference><Reference><Citation>Willan J, King AJ, Hayes S, Collins GP, Peniket A. Care of haematology patients in a COVID-19 epidemic. Br J Haematol. 2020;189:241-3.</Citation></Reference><Reference><Citation>Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323:1843-4.</Citation></Reference><Reference><Citation>Drayson, MT, Bowcock, S, Planche, T, Iqbal, G, Pratt, G, Yong, K, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019;20:1760-72.</Citation></Reference><Reference><Citation>Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer Journal. 2017;7:e546.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001530 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001530 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32480420
|texte= Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32480420" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |